Background: F901318 is a new antifungal agent with a novel mechanism of action with activity against Aspergillus species. We investigated the in vitro activity of F901318 against a collection of Aspergillus isolates.
Introduction
Aspergillus species account for the majority of invasive mould infections. 1 Invasive aspergillosis is a life-threatening disease mainly affecting immunocompromised patients. Only two classes of antifungal agents are licensed for the primary therapy of invasive aspergillosis, namely the triazoles and amphotericin B. Since 2002, voriconazole has been the mainstay of therapy for invasive aspergillosis. 2 Since then, also because of improved diagnostics and supportive care management, the survival rate of patients with invasive aspergillosis improved from ,30% to .70% in recent years. 3, 4 The improved survival rate of patients with invasive aspergillosis is threatened by the worldwide emergence of azole resistance in Aspergillus fumigatus. The prevalence of azole resistance in A. fumigatus isolates ranges between 1% and .10%, depending on the geographical region. 5 However, studies performed in high-risk patient groups, such as haematology or ICU patients, indicate that these prevalence rates may be up to 30%, 6, 7 but these high resistance rates are probably restricted to hospitals in areas with high prevalence of azole resistance. Azole-resistant invasive aspergillosis seems to be mainly due to resistance mutations associated with environmental selection, i.e. TR 34 /L98H or TR 46 / Y121F/T289A, and these mutations account for 67% of resistance in Belgium and .80% of resistance cases in the Netherlands. 8 Importantly, case series indicate that azole-resistant invasive aspergillosis is associated with treatment failure. 8 Emerging species like Aspergillus tubingensis and Aspergillus calidoustus often have increased MICs of one or multiple antifungal agents. 9, 10 Therefore, the clinical development of new antifungal drug classes is critical to overcome the current and future challenges in the management of invasive aspergillosis. 11 This is a novel target, and F901318 has activity against Aspergillus, Scedosporium and Fusarium species and endemic fungi. 11, 12 Pharmacokinetic studies in mice indicate good tissue distribution and the agent is now under evaluation in Phase I trials in both oral and intravenous formulations. 11 In this study, we evaluated the in vitro activity of F901318 against a collection of phenotypic azole-resistant A. fumigatus isolates. In addition, the activity against a collection of other difficult-to-treat Aspergillus species, including Aspergillus nidulans, Aspergillus flavus complex, Aspergillus calidoustus and Aspergillus tubingensis was investigated.
Materials and methods

Isolates
A total of 213 Aspergillus isolates were used in this study. A total of 143 A. fumigatus sensu stricto isolates were used, of which 133 were azole resistant [25 TR 34 /L98H; 25 TR 46 /Y121F/T289A, 33 were A. fumigatus with cyp51A-associated point mutations (25 G54, 1 G432 and 7 M220) and 50 were azole-resistant A. fumigatus without known resistance mechanisms]. Ten azole-susceptible A. fumigatus isolates were used as WT controls. Furthermore, a collection of A. calidoustus (25 isolates), Aspergillus flavus (10), Aspergillus nidulans (10) and A. tubingensis (25) were tested. All isolates were from the fungal culture collections of the Radboud University Medical Center and the Canisius Wilhelmina Hospital, Nijmegen, the Netherlands. The identification of isolates was performed by sequencing the b-tubulin gene (A. fumigatus, A. nidulans, A. flavus and A. tubingensis) or the calmodulin gene (A. calidoustus). The full cyp51A gene of A. fumigatus sensu stricto was sequenced as previously described. 13 
Susceptibility testing
The susceptibility of Aspergillus isolates to F901318 was compared with their susceptibility to voriconazole, itraconazole, isavuconazole, posaconazole, amphotericin B and anidulafungin. Susceptibility testing of voriconazole, itraconazole, isavuconazole, posaconazole, amphotericin B and anidulafungin was performed according to the EUCAST broth microdilution reference method (E.Def 9.2). F901318 was dissolved in DMSO. The concentration range of all drugs was 0.016-16 mg/L. Endpoints were determined after 48 h of incubation at 100% inhibition compared with growth control except for anidulafungin, for which the endpoint was defined as the lowest concentration in which abnormal, short and branched hyphal elements were observed after 24 h of incubation.
Statistics
Susceptibility testing was performed in duplicate for F901318 and the mean MIC was used for comparison and calculation of geometric mean (GM) MICs. For the other antifungals a single MIC value was determined. For F901318, when the mean of two measurements was between two dilutions, the next higher dilution was used to calculate the MIC 50 and MIC 90 . Calculations were performed by the use of GraphPad Prism (version 5.03). For comparing the GM MICs for A. fumigatus isolates, Kruskal-Wallis analysis of variance was used. Figure 1 . F901318 was most active against A. flavus and least active against A.
Results
MIC distributions of F901318 are shown in
calidoustus. The highest MIC found for A. fumigatus, A. nidulans and A. tubingensis was 0.25 mg/L. The highest MICs for A. flavus and A. calidoustus were 0.125 and 0.5 mg/L, respectively. The essential agreement between the duplicates was 91%. The agreement within one dilution was 100%.
The MIC 50 , MIC 90 and MIC ranges of all tested antifungals are shown in Table 1 , grouped based on Aspergillus species and based on their azole resistance mechanism. The MICs of F901318 were in general lower than the MICs of the different azoles and amphotericin B. To test whether the observed differences in F901318 MICs (Figure 1) for the A. fumigatus subgroups were statistically significant, the GM MICs for these isolates were compared with the GM MICs for phenotypically WT A. fumigatus isolates. For TR 34 /L98H isolates the F901318 MIC results were in the same range as for phenotypically WT A. fumigatus isolates. In contrast, the F901318 GM MIC for TR 46 /Y121F/T289A isolates was one dilution higher than that for the WT isolates (P , 0.01), although this did not result in a higher MIC 90 . The F901318 GM MIC for A. fumigatus with cyp51A-associated point mutations was one dilution step lower than for WT isolates (for both G54 and M220 mutations when analysed individually) (P , 0.01). The F901318 GM MIC for other subgroups was not significantly different from the F901318 GM MIC for WT isolates.
Some A. flavus isolates had reduced susceptibility to azoles and/or amphotericin B. F901318 showed potent activity against all of these isolates. Several A. tubingensis isolates had a high MIC of voriconazole while isolates of A. nidulans had a slightly increased MIC of amphotericin B compared with A. fumigatus WT isolates. The MIC of F901318 was consistently low (for both A. tubingensis and A. nidulans). A. calidoustus had higher MICs of the azoles, amphotericin B and anidulafungin compared with A. fumigatus. The MIC 50 and MIC 90 of F901318 were also higher compared with A. fumigatus, but an MIC .0.5 mg/L was not found.
Discussion
Despite optimal antifungal treatment, invasive aspergillosis remains a difficult-to-manage disease, especially when Aspergillus species with intrinsic or acquired resistance are involved. Therefore, development of new antifungal compounds is paramount. In vitro and in vivo activity of F901318 has been demonstrated against A. fumigatus previously. 11 Here, we demonstrated that F901318 has a potent in vitro activity against A. fumigatus isolates with intrinsic and acquired azole resistance. All A. fumigatus isolates had an F901318 MIC of 0.25 mg/L. No substantial implications of the specific azole resistance mechanism for the activity of F901318 were demonstrated.
Subgroup comparisons of A. fumigatus isolates showed small differences in the GM MIC when isolates with TR 46 /Y121F/T289A and single-point mutations were compared with phenotypically WT isolates. The differences in GM MIC cannot be explained by the azole resistance mechanism, as the target of F901318 is different from the target of azoles. It is possible that the differences for TR 46 /Y121F/T289A can be explained by the recent emergence of these TR 46 /Y121F/T289A mutants and their related linage separate from the WT isolates, rather than by the mutation itself. . MIC distributions of F901318 for Aspergillus species grouped based on species and for A. fumigatus based on resistance mechanism. Susceptibility testing of F901318 was performed using the EUCAST methodology, with 100% growth inhibition as endpoint. Susceptibility testing was performed in duplicate; the highest MIC for the duplicates was used to draw the figures.
In addition to A. fumigatus isolates, we have tested several other, difficult-to-treat Aspergillus species with high MICs of several antifungals. A. flavus is globally the second most common species causing invasive aspergillosis. 15 Most isolates of A. flavus are susceptible to triazoles and echinocandins, but have amphotericin B MICs between 1 and 4 mg/L. 16 Although still rare, resistance to azoles was recently described. 17 Invasive A. nidulans infections are primarily associated with chronic granulomatous disease, with a higher mortality compared with A. fumigatus.
18
Notably, A. nidulans isolates are less susceptible to amphotericin B in vitro. 19 A. tubingensis is a black Aspergillus species, morphologically identical to A. niger. It is the fifth most identified species and has reduced susceptibility to azoles compared with A. niger.
9 A. calidoustus is a relatively rare cause of Aspergillus disease, but is increasingly seen in lung transplant patients on mould-active azole prophylaxis. 20 It shows resistance to medical triazoles in vitro and has reduced susceptibility to amphotericin B compared with A. fumigatus. 10, 20 In vitro evaluation of F901318 revealed potent activity against all the non-fumigatus Aspergillus species evaluated in this study.
In conclusion, F901318 showed excellent in vitro activity against all isolates tested in this study and is a much-needed new antifungal class for the treatment of invasive aspergillosis, in a setting of emerging azole resistance. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24: 635-42. Isolates are grouped based on species; A. fumigatus was further grouped based on resistance mechanism.
MIC testing (and minimum effective concentration testing for anidulafungin) were performed in accordance with EUCAST broth microdilution.
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